Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 14 points (0.1%) at 16,024 as of Friday, Nov. 22, 2013, 11:45 AM ET. The NYSE advances/declines ratio sits at 1,437 issues advancing vs. 1,443 declining with 136 unchanged.

The Health Services industry currently sits down 0.1% versus the S&P 500, which is up 0.2%. On the negative front, top decliners within the industry include Covance ( CVD), down 1.2%, DaVita HealthCare Partners ( DVA), down 1.1%, Grifols ( GRFS), down 0.8% and St Jude Medical ( STJ), down 0.5%. Top gainers within the industry include Boston Scientific ( BSX), up 0.8%, Cigna ( CI), up 0.7% and Fresenius Medical Care AG & Co. KGaA ( FMS), up 0.5%.

TheStreet would like to highlight 5 stocks pushing the industry lower today:

5. Mednax ( MD) is one of the companies pushing the Health Services industry lower today. As of noon trading, Mednax is down $1.20 (-1.1%) to $109.88 on light volume. Thus far, 83,263 shares of Mednax exchanged hands as compared to its average daily volume of 233,800 shares. The stock has ranged in price between $109.85-$111.00 after having opened the day at $110.87 as compared to the previous trading day's close of $111.08.

MEDNAX, Inc., together with its subsidiaries, provides newborn, maternal-fetal, pediatric subspecialties, and anesthesia care physician services in the United States and Puerto Rico. Mednax has a market cap of $5.5 billion and is part of the health care sector. The company has a P/E ratio of 20.7, above the S&P 500 P/E ratio of 17.7. Shares are up 39.7% year to date as of the close of trading on Thursday. Currently there are 6 analysts that rate Mednax a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Mednax as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, growth in earnings per share and increase in net income. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full Mednax Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

4. As of noon trading, Mindray Medical International Limited ADR r ( MR) is down $0.61 (-1.5%) to $39.46 on average volume. Thus far, 426,018 shares of Mindray Medical International Limited ADR r exchanged hands as compared to its average daily volume of 806,600 shares. The stock has ranged in price between $39.45-$40.08 after having opened the day at $40.00 as compared to the previous trading day's close of $40.07.

Mindray Medical International Limited, through its subsidiary, Shenzhen Mindray, develops, manufactures, and markets medical devices worldwide. It operates in three segments: Patient Monitoring and Life Support Products, In-Vitro Diagnostic Products, and Medical Imaging Systems. Mindray Medical International Limited ADR r has a market cap of $4.7 billion and is part of the health care sector. The company has a P/E ratio of 21.9, above the S&P 500 P/E ratio of 17.7. Shares are up 22.5% year to date as of the close of trading on Thursday. Currently there are 4 analysts that rate Mindray Medical International Limited ADR r a buy, 1 analyst rates it a sell, and 3 rate it a hold.

TheStreet Ratings rates Mindray Medical International Limited ADR r as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and good cash flow from operations. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Mindray Medical International Limited ADR r Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

3. As of noon trading, Sirona Dental Systems ( SIRO) is down $1.11 (-1.5%) to $71.50 on average volume. Thus far, 272,711 shares of Sirona Dental Systems exchanged hands as compared to its average daily volume of 460,700 shares. The stock has ranged in price between $71.11-$73.94 after having opened the day at $72.95 as compared to the previous trading day's close of $72.61.

Sirona Dental Systems, Inc., together with its subsidiaries, develops, manufactures, and markets dental equipment for dentists worldwide. It operates in four segments: Dental CAD/CAM Systems, Imaging Systems, Treatment Centers, and Instruments. Sirona Dental Systems has a market cap of $4.0 billion and is part of the health care sector. The company has a P/E ratio of 28.1, above the S&P 500 P/E ratio of 17.7. Shares are up 12.6% year to date as of the close of trading on Thursday. Currently there are 9 analysts that rate Sirona Dental Systems a buy, 1 analyst rates it a sell, and 1 rates it a hold.

TheStreet Ratings rates Sirona Dental Systems as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, compelling growth in net income and good cash flow from operations. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Sirona Dental Systems Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Zimmer Holdings ( ZMH) is down $0.47 (-0.5%) to $88.70 on light volume. Thus far, 413,554 shares of Zimmer Holdings exchanged hands as compared to its average daily volume of 1.1 million shares. The stock has ranged in price between $88.38-$89.36 after having opened the day at $89.36 as compared to the previous trading day's close of $89.17.

Zimmer Holdings, Inc., through its subsidiaries, engages in the design, development, manufacture, and marketing of orthopedic reconstructive devices, spinal and trauma devices, biologics, dental implants, and related surgical products in the Americas, Europe, and the Asia Pacific. Zimmer Holdings has a market cap of $15.1 billion and is part of the health care sector. The company has a P/E ratio of 22.4, above the S&P 500 P/E ratio of 17.7. Shares are up 32.5% year to date as of the close of trading on Thursday. Currently there are 9 analysts that rate Zimmer Holdings a buy, 1 analyst rates it a sell, and 14 rate it a hold.

TheStreet Ratings rates Zimmer Holdings as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Zimmer Holdings Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Baxter International ( BAX) is down $0.59 (-0.9%) to $67.82 on light volume. Thus far, 878,982 shares of Baxter International exchanged hands as compared to its average daily volume of 3.5 million shares. The stock has ranged in price between $67.78-$68.68 after having opened the day at $68.56 as compared to the previous trading day's close of $68.41.

Baxter International Inc., through its subsidiaries, develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. Baxter International has a market cap of $37.5 billion and is part of the health care sector. The company has a P/E ratio of 17.5, below the S&P 500 P/E ratio of 17.7. Shares are up 2.6% year to date as of the close of trading on Thursday. Currently there are 5 analysts that rate Baxter International a buy, no analysts rate it a sell, and 9 rate it a hold.

TheStreet Ratings rates Baxter International as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, good cash flow from operations, expanding profit margins, notable return on equity and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Baxter International Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).

null